Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

216 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12.
Fokas E, Allgäuer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R, Kuhnt T, Staib L, Brunner T, Grosu AL, Schmiegel W, Jacobasch L, Weitz J, Folprecht G, Schlenska-Lange A, Flentje M, Germer CT, Grützmann R, Schwarzbach M, Paolucci V, Bechstein WO, Friede T, Ghadimi M, Hofheinz RD, Rödel C; German Rectal Cancer Study Group. Fokas E, et al. Among authors: hofheinz rd. J Clin Oncol. 2019 Dec 1;37(34):3212-3222. doi: 10.1200/JCO.19.00308. Epub 2019 May 31. J Clin Oncol. 2019. PMID: 31150315 Clinical Trial.
Phase I trial of cetuximab in combination with capecitabine, weekly irinotecan, and radiotherapy as neoadjuvant therapy for rectal cancer.
Hofheinz RD, Horisberger K, Woernle C, Wenz F, Kraus-Tiefenbacher U, Kähler G, Dinter D, Grobholz R, Heeger S, Post S, Hochhaus A, Willeke F. Hofheinz RD, et al. Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1384-90. doi: 10.1016/j.ijrobp.2006.07.005. Epub 2006 Sep 18. Int J Radiat Oncol Biol Phys. 2006. PMID: 16979839 Clinical Trial.
Cetuximab in combination with capecitabine, irinotecan, and radiotherapy for patients with locally advanced rectal cancer: results of a Phase II MARGIT trial.
Horisberger K, Treschl A, Mai S, Barreto-Miranda M, Kienle P, Ströbel P, Erben P, Woernle C, Dinter D, Kähler G, Hochhaus A, Post S, Willeke F, Wenz F, Hofheinz RD; MARGIT (Mannheimer Arbeitsgruppe für Gastrointestinale Tumoren). Horisberger K, et al. Among authors: hofheinz rd. Int J Radiat Oncol Biol Phys. 2009 Aug 1;74(5):1487-93. doi: 10.1016/j.ijrobp.2008.10.014. Epub 2009 Jan 7. Int J Radiat Oncol Biol Phys. 2009. PMID: 19131187 Clinical Trial.
KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer.
Erben P, Ströbel P, Horisberger K, Popa J, Bohn B, Hanfstein B, Kähler G, Kienle P, Post S, Wenz F, Hochhaus A, Hofheinz RD. Erben P, et al. Among authors: hofheinz rd. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1032-8. doi: 10.1016/j.ijrobp.2010.06.043. Epub 2010 Oct 13. Int J Radiat Oncol Biol Phys. 2011. PMID: 20947270 Clinical Trial.
Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial.
Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, Müller L, Link H, Moehler M, Kettner E, Fritz E, Hieber U, Lindemann HW, Grunewald M, Kremers S, Constantin C, Hipp M, Hartung G, Gencer D, Kienle P, Burkholder I, Hochhaus A. Hofheinz RD, et al. Lancet Oncol. 2012 Jun;13(6):579-88. doi: 10.1016/S1470-2045(12)70116-X. Epub 2012 Apr 13. Lancet Oncol. 2012. PMID: 22503032 Clinical Trial.
216 results